



November 5, 1999

1406 99 107-6 8900

Dockets Management Branch  
Division of Management Systems and Policy  
Office of Human Resources and Management Services  
Food and Drug Administration  
5630 Fishers Lane, Room 1061 (HFA-305)  
Rockville, MD 20852

**Re: Docket No. 99D-2212**  
**Draft Guidance On Quality Systems Regulation Information For Various**  
**Premarket Submissions**

In response to the Federal Register Notice of August 3, 1999, Allergan, Inc. is hereby commenting on the above-cited draft guidance document.

Allergan appreciates the promulgation of guidance intended to clarify Agency expectations regarding data and information to be provided in marketing applications. Nonetheless, we respectfully submit that the documentation to be required, per the proposed guidance, is in excess of that which is necessary for FDA to meet its statutory mandate and is, therefore, unduly burdensome. In particular, we believe the guidance should be modified as follows:

- The requirement for providing a design control dossier and a manufacturing dossier for *every PMA supplement* is unwarranted. FDA has recently published the "Draft Guidance: Likelihood of Facilities Inspections When Modifying Devices Subject to Premarket Approval." We recommend that the requirements for submission of QS Regulation information be limited to those 180-day PMA supplements where a pre-approval inspection is "likely" per the cited draft guidance. Further, once a manufacturer has submitted a manufacturing dossier to a specified PMA, 180-day supplements should only be required to include information that differs from that submitted previously.

Similarly, only those PMA supplements requesting approval for design changes should require design dossiers, with the level of required information commensurate with the significance of the design change. For example, a PMA

99D-2212

C 6

**Allergan Surgical Products**


**Draft Guidance On Quality Systems Regulation Information For Various  
Premarket Submissions**

supplement for a labeling change to add a new claim could be adequately addressed by providing information on the design change procedures by which the new labeling was qualified.

- The requirement for manufacturers to have a design control dossier available, upon request, for devices subject to 510(k) clearance suggests that such documentation could be requested as part of the determination of substantial equivalence. Substantial equivalence determinations should be based on the comparison of the proposed device to a legally marketed predicate device and *not* based upon review of the design procedures.
- The requirement for manufacturers to maintain design control dossiers *at their manufacturing facility* to support premarket notifications is also unwarranted. Each facility should only be required to maintain Quality System Regulation information relevant to procedures conducted at that site. Thus, where all design is performed at another site, the required design control information at the manufacturing site should be limited to the change control procedures in effect at that site.
- We believe that Item #3 on page 9 of the draft guidance, which states that a manufacturer should highlight its lack of expertise with a new process (when validating something for the first time), is highly inappropriate. This infers that such manufacturers' validations will be scrutinized at a much higher level than validations performed by other manufacturers. We believe it is important that FDA apply consistent criteria in its review of all marketing applications.

Thank you for the opportunity to comment on this draft document. Please feel free to contact me if you require further information on this matter.

Sincerely,



Marcia S. Yaross, Ph.D.  
Director, Worldwide Regulatory Affairs  
and Medical Compliance

**FedEx****Express  
Shipping  
Request**For use by PowerShip  
Customers only

8129 1792 5059



Form I.D. No.

0205

0101180331

331

WCSL 3/99

PART 154819

Rev. 11/98

©1994-98

Federal Express Corporation

Sender's FedEx Account Number

0900-1170-7

8129 1792 5059

Form

I.D. No.

0205

From M. Yaross, VK-2A

Ship Date 11-5-99

ALLERGAN INC

2525 DUPONT DR

IRVINE, CA 92612-1599

To (If Hold for Pickup, Print FedEx Address Here.) (We Cannot Deliver to P.O. Boxes or P.O. Zip Codes.)

Dockets Management Branch  
Division of Management Systems & Policy  
Office of Human Resources & Management Services  
Food and Drug Administration  
5630 Fishers Lane, Room 1061 (HFA-305)  
Rockville, MD 20852

Release No.

Phone No.

Reference Info 2001200035

Special  
Handling☐ HOLD Weekday at  
FedEx Location☐ HOLD Saturday at  
FedEx Location☐ Saturday  
Delivery☐ Sunday  
Delivery☐ Dangerous  
Goods☐ Dry  
IceServices  
WEIGHT DECLARED VALUE  
NDV

FedEx Priority Overnight

☒ FedEx  
Letter  
☐ FedEx  
Box  
☐ FedEx  
Pak  
☐ Other Pkg.

FedEx Standard Overnight

☐ FedEx  
Letter  
☐ FedEx  
Box  
☐ FedEx  
Pak  
☐ Other Pkg.

FedEx 2Day

☐ FedEx  
Letter  
☐ FedEx  
Pak  
☐ Other Pkg.

FedEx First Overnight

☐ FedEx  
Letter  
☐ Other Pkg.

FedEx Express Saver

☐ FedEx  
Letter  
☐ Other

FedEx 1Day Freight

☐ Other

FedEx 2Day Freight

☐ Other

FedEx 3Day Freight

☐ Other  
Pkg.ALLERGAN SALES, INC.  
COMPANY MAIL DEPT.  
2525 DUPONT DRIVE  
IRVINE  
(714)246-4753

CA 92612-1599

SHIP DATE: 05NOV99  
ACC # 090011707

ACTUAL WGT: 1 LBS SCALE

# The World LE

SEE ADDRESS LABEL ON PACKAGE FOR  
THIS SHIPMENT TO MD 20852

8129 1792 5059

FedEx

8129 1792 5059

REF: 2001200035

PRIORITY OVERNIGHT

MON

cad # 0011834 05NOV99

TRK# 8129 1792 5059

FORM  
0201

Deliver by:

08NOV99

20852 -MD-US

IAD AA

XA EDGA



153078-077 RIT 1059